Loading your page…
Loading your page…
Published by European Society of Cardiology · 78 pages · Class I
Defines aggressive LDL-C targets for high and very high CV risk: <1.4 mmol/L (<55 mg/dL) for very high risk with ≥50% reduction. PCSK9 inhibitors recommended for patients not at target on maximum tolerated statin + ezetimibe. Updated risk calculator SCORE2 for European populations.
Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.
Free plan includes 10 guideline reads per day · No credit card required